Metabolic markers predict response to immunotherapy before lung cancer surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether certain markers in your blood or tissue can predict how well immunotherapy works before surgery for early-stage lung cancer. It aims to find out who benefits most from this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer (the most common type) that is at stage IB, II, or IIIA, meaning it has not spread widely and doctors plan to remove it with surgery.
- You are feeling well enough to be up and about (ECOG performance status 0 or 1).
- Your organs and bone marrow are working well, as shown by standard blood tests.
- You have not had any prior chemotherapy, radiation, or immunotherapy for your lung cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether certain white blood cells (called neutrophils) in your tumor can predict how well a combination of chemotherapy and immunotherapy works before surgery for lung cancer. If you qualify, you would receive this treatment and then have surgery, and researchers would track your response.
This study looks at a treatment plan that uses immunotherapy before and after surgery for non-small cell lung cancer. The goal is to see if this approach helps patients do better and to find out which patients benefit most.
This trial tests whether a blood test (ctDNA) can help predict how well a combination of chemotherapy and immunotherapy (and sometimes radiation) works before surgery for non-small cell lung cancer. It aims to see if the blood test can detect small amounts of remaining cancer to guide further treatment.
This study looks at a simple blood test to see if it can predict how well your cancer will respond to immunotherapy. You will give blood samples before and during treatment, and the researchers will analyze small particles in your blood to find clues about your likely response.
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
This study looks for blood or tissue markers that can predict who benefits from immunotherapy given before surgery for non-small cell lung cancer. It may help doctors better choose treatment in the future.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.